PMID- 25142290
OWN - NLM
STAT- MEDLINE
DCOM- 20151102
LR  - 20180816
IS  - 1601-5215 (Electronic)
IS  - 0924-2708 (Linking)
VI  - 26
IP  - 4
DP  - 2014 Aug
TI  - BDNF and S100B in psychotic disorders: evidence for an association with treatment 
      responsiveness.
PG  - 223-9
LID - 10.1017/neu.2013.59 [doi]
AB  - OBJECTIVE: Brain-derived neurotrophic factor (BDNF) and S100B are involved in 
      brain plasticity processes and their serum levels have been demonstrated to be 
      altered in patients with psychoses. This study aimed to identify subgroups of 
      patients with psychotic disorders across diagnostic boundaries that show a 
      specific symptom profile or response to treatment with antipsychotics, by 
      measuring serum levels of BDNF and S100B. METHODS: The study sample consisted of 
      58 patients with DSM-IV psychotic disorders. Comprehensive Assessment of Symptoms 
      and History (CASH), Positive and Negative Syndrome Scale (PANSS) and Clinical 
      Global Impression scale for severity and improvement (CGI-S/CGI-I) were applied 
      at baseline and after 6 weeks of antipsychotic treatment. At both time points, 
      serum levels of BDNF and S100B were measured and compared with a matched control 
      sample. RESULTS: Baseline BDNF and S100B levels were significantly lower in 
      patients as compared with controls and did not change significantly during 
      treatment. Dividing the patient sample according to baseline biochemical 
      parameters (low and high 25% and middle 50%), no differences in symptom profiles 
      or outcome were found with respect to BDNF. However, the subgroups with low and 
      high S100B levels had higher PANSS scores than the middle subgroup. In addition, 
      the high subgroup still showed significantly more negative symptoms after 
      treatment, whereas the low subgroup showed more positive symptoms compared with 
      the other subgroups. CONCLUSION: Serum levels of BDNF and S100B are lowered in 
      patients with psychotic disorders across diagnostic boundaries. The differences 
      between high and low S100B subgroups suggest a relationship between S100B, 
      symptom dimensions and treatment response, irrespective of diagnostic categories.
FAU - van de Kerkhof, Noortje W A
AU  - van de Kerkhof NW
AD  - 1Vincent van Gogh Institute for Psychiatry,Centre of Excellence for 
      Neuropsychiatry,Venray,The Netherlands.
FAU - Fekkes, Durk
AU  - Fekkes D
AD  - 2Erasmus Medical Centre,Departments of Psychiatry and Clinical 
      Chemistry,Rotterdam,The Netherlands.
FAU - van der Heijden, Frank M M A
AU  - van der Heijden FM
AD  - 1Vincent van Gogh Institute for Psychiatry,Centre of Excellence for 
      Neuropsychiatry,Venray,The Netherlands.
FAU - Verhoeven, Willem M A
AU  - Verhoeven WM
AD  - 1Vincent van Gogh Institute for Psychiatry,Centre of Excellence for 
      Neuropsychiatry,Venray,The Netherlands.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Neuropsychiatr
JT  - Acta neuropsychiatrica
JID - 9612501
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (S100 Calcium Binding Protein beta Subunit)
RN  - 0 (S100B protein, human)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*blood/drug therapy
MH  - S100 Calcium Binding Protein beta Subunit/*blood
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2014/08/22 06:00
MHDA- 2015/11/03 06:00
CRDT- 2014/08/22 06:00
PHST- 2014/08/22 06:00 [entrez]
PHST- 2014/08/22 06:00 [pubmed]
PHST- 2015/11/03 06:00 [medline]
AID - S0924270813000598 [pii]
AID - 10.1017/neu.2013.59 [doi]
PST - ppublish
SO  - Acta Neuropsychiatr. 2014 Aug;26(4):223-9. doi: 10.1017/neu.2013.59.